Nothing Special   »   [go: up one dir, main page]

AU2001278503A1 - Novel guanidino derivatives as inhibitors of cell adhesion - Google Patents

Novel guanidino derivatives as inhibitors of cell adhesion

Info

Publication number
AU2001278503A1
AU2001278503A1 AU2001278503A AU7850301A AU2001278503A1 AU 2001278503 A1 AU2001278503 A1 AU 2001278503A1 AU 2001278503 A AU2001278503 A AU 2001278503A AU 7850301 A AU7850301 A AU 7850301A AU 2001278503 A1 AU2001278503 A1 AU 2001278503A1
Authority
AU
Australia
Prior art keywords
cell
formula
compounds
inhibitors
cell adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278503A
Inventor
Thomas R. Gadek
Jean-Francois Gourvest
Jochen Knolle
Robert Mcdowell
Anushirwan Peyman
Jean-Marie Ruxer
David Will
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Genentech Inc
Original Assignee
Aventis Pharma Deutschland GmbH
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH, Genentech Inc filed Critical Aventis Pharma Deutschland GmbH
Publication of AU2001278503A1 publication Critical patent/AU2001278503A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to acylguanidino derivatives of the formula I, <CHEM> in which R<1>, R<2>, R<3>, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as pharmaceutical active ingredients, and pharmaceutical compositions comprising them.
AU2001278503A 2000-07-28 2001-07-23 Novel guanidino derivatives as inhibitors of cell adhesion Abandoned AU2001278503A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00116385 2000-07-28
EP00116385A EP1176145A1 (en) 2000-07-28 2000-07-28 Novel guanidino derivatives as inhibitors of cell adhesion
PCT/EP2001/008485 WO2002010168A1 (en) 2000-07-28 2001-07-23 Novel guanidino derivatives as inhibitors of cell adhesion

Publications (1)

Publication Number Publication Date
AU2001278503A1 true AU2001278503A1 (en) 2002-02-13

Family

ID=8169381

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278503A Abandoned AU2001278503A1 (en) 2000-07-28 2001-07-23 Novel guanidino derivatives as inhibitors of cell adhesion

Country Status (7)

Country Link
US (1) US7259159B2 (en)
EP (2) EP1176145A1 (en)
JP (1) JP5002109B2 (en)
AT (1) ATE432934T1 (en)
AU (1) AU2001278503A1 (en)
DE (1) DE60138893D1 (en)
WO (1) WO2002010168A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870541B1 (en) 2004-05-18 2006-07-14 Proskelia Sas ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19653646A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Substituted purine derivatives, processes for their preparation, agents containing them and their use
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
FR2786184B1 (en) * 1998-11-24 2002-09-20 Hoechst Marion Roussel Inc NOVEL BENZOFURANE DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
US7259159B2 (en) 2007-08-21
EP1176145A1 (en) 2002-01-30
JP5002109B2 (en) 2012-08-15
US20030203896A1 (en) 2003-10-30
ATE432934T1 (en) 2009-06-15
DE60138893D1 (en) 2009-07-16
EP1313737A1 (en) 2003-05-28
WO2002010168A1 (en) 2002-02-07
JP2004505084A (en) 2004-02-19
EP1313737B1 (en) 2009-06-03

Similar Documents

Publication Publication Date Title
MY122269A (en) Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronection receptor antagonists
BG104630A (en) Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
CA2225366A1 (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
MY119118A (en) Thiophenopyrimidines
DE60216127D1 (en) Benzothiepine als ileal bile acid transport inhibotoren
CA2233285A1 (en) Pyrazolopyrimidines as crf receptor antagonists
IL160689A0 (en) Benzothiazepine derivatives for treatment of hyperlipidemia
NZ514477A (en) Adamantane derivatives
HK1065258A1 (en) Benzothiazepine and benzothiadiazepine derivativeswith ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
GB0121337D0 (en) Chemical compounds
MY137508A (en) Chemical compounds
IL144725A0 (en) Novel guanidine derivatives as inhibitors of cell adhesion
CL2003002042A1 (en) COMPOUNDS DERIVED FROM 3,9-DIAZABICICLO [3.3.1] NONENE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND AS A RENIN INHIBITOR (RAS), TO TREAT HYPERTENSION, CONGESTIVE HEART FAILURE, PULMONARY HYPERTENSION, RENAL INSUFFICIENCY, ATEROSCLEROS
CA2336412A1 (en) Medicament for treatment of diabetes
MY133246A (en) Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them
NZ515614A (en) Bisphosphonate compositions with a discontinuous wax coating to aid oesophageal transit
AP2004003160A0 (en) Tolterodine salts
MY122631A (en) Substituted purine derivatives as inhibitors of cell adhesion
AU2001278503A1 (en) Novel guanidino derivatives as inhibitors of cell adhesion
AU2674201A (en) Thienylalanine derivatives as inhibitors of cell adhesion
HUP0202710A2 (en) Vitronectin receptor antagonists, pharmaceutical compositions containing them and their use
GR3018329T3 (en) Novel benzopyran derivatives and processes for the preparation thereof.